Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Ping-Hsun Chen"'
Autor:
陳秉訓 Ping-Hsun Chen
Publikováno v:
交大法學評論, Iss 13, Pp 89-121 (2023)
本文意在參酌美國聯邦《經濟間諜法》（Economic Espionage Act, EEA）與《模範刑法法典》（Model Penal Code, MPC）第5.01條之著手犯之法制，來思考我國營業秘密法犯罪行為中的未遂犯意涵。本文指出
Externí odkaz:
https://doaj.org/article/89e751cb1ea441758ccdf519672b6361
Autor:
陳秉訓 Ping-Hsun Chen
Publikováno v:
交大法學評論, Iss 10, Pp 49-97 (2022)
2019 年起藥事法實施專利連結制度，於學名藥廠申請學名藥藥品許可證之過程中，提供原藥廠提早解決專利權侵害爭議之機制。本文意在藉由過去智財法院涉及藥品專利的民事訴訟裁定，共
Externí odkaz:
https://doaj.org/article/7295dc7be61e492ebe6f2faac898f3e5
Autor:
Ping-Hsun Chen, 陳品勳
99
The article is discussed the broken discarded tile and brick after cleaning with the discarded concrete blocks stirred them to the recycled coarse aggregates in different ratio, and replaced the coarse aggregates poured to the recycled concre
The article is discussed the broken discarded tile and brick after cleaning with the discarded concrete blocks stirred them to the recycled coarse aggregates in different ratio, and replaced the coarse aggregates poured to the recycled concre
Externí odkaz:
http://ndltd.ncl.edu.tw/handle/16544196340501783648
Autor:
PING-HSUN CHEN
Publikováno v:
Biotechnology Law Report. 41:240-250
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6e23d6bc0a2adb1886fed3c418d0cd5
https://doi.org/10.1089/blr.2022.29285.phc
https://doi.org/10.1089/blr.2022.29285.phc
Autor:
Ping-Hsun Chen
Publikováno v:
Biotechnology Law Report. 41:78-85
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9fc21ab722348261a18b46122155145e
https://doi.org/10.1089/blr.2022.29262.phc
https://doi.org/10.1089/blr.2022.29262.phc
Autor:
陳秉訓 Ping-Hsun Chen
Publikováno v:
Kējì Fǎxué Pínglùn, Vol 11, Iss 1, Pp 155-220 (2014)
專家證人在美國專利訴訟中扮演重要的角色。專利訴訟常涉及技術議題，需要技術專家的參與來幫助解釋請求項或協助陪審團瞭解專利技術或侵權物。當處理可專利性爭點時，技術專家則是
Externí odkaz:
https://doaj.org/article/5c667426679449fa8dea0dcec8c73b96
Autor:
Ping-Hsun Chen
Publikováno v:
Biotechnology Law Report. 40:174-183
This article reports Taiwan's efforts to replicate remdesivir to prepare for combating COVID-19. There were two state-funded institutions and two private pharmaceutical companies working on remdesi...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89202273e4f59e703c9c7dc6b0692dd0
https://doi.org/10.1089/blr.2021.29227.phc
https://doi.org/10.1089/blr.2021.29227.phc
Autor:
Ping-Hsun Chen
Publikováno v:
Biotechnology Law Report. 39:452-457
IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc., 966 F.3d 1374 (Fed. Cir. 2020), shows a case of inaccurate translation leading the court to find the asserted claims invalid. The ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::faca319ea294152ad8ac605126fcba92
https://doi.org/10.1089/blr.2020.29208.phc
https://doi.org/10.1089/blr.2020.29208.phc
Autor:
Ping-Hsun Chen
Publikováno v:
Biotechnology Law Report. 39:25-32
This article explores Shire Development, LLC v. Watson Pharmaceuticals, Inc., 848 F.3d 981 (Fed. Cir. 2017) and illustrates some implications for designing around a MMX-based tablet drug, Lialda. T...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::728df82483fd4ac2fd806de978126133
https://doi.org/10.1089/blr.2019.29155.pc
https://doi.org/10.1089/blr.2019.29155.pc
Autor:
Ping-Hsun Chen1
Publikováno v:
Brooklyn Journal of Corporate, Financial & Commercial Law. 2019, Vol. 13 Issue 2, p395-416. 22p.